Reference : Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised...
Scientific journals : Article
Human health sciences : Rheumatology
Human health sciences : Public health, health care sciences & services
http://hdl.handle.net/2268/56763
Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial
English
Reginster, Jean-Yves mailto [Université de Liège - ULiège > Département des sciences de la santé publique > Epidémiologie et santé publique >]
Deroisy, Rita mailto [Université de Liège - ULiège > > Médecine de l'appareil locomoteur >]
Rovati, Lucio C [> >]
Lee, Richard L [> >]
Lejeune, Eric mailto [Université de Liège - ULiège > > Médecine de l'appareil locomoteur >]
Bruyère, Olivier mailto [Université de Liège - ULiège > Département des sciences de la santé publique > Epidémiologie et santé publique >]
Giacovelli, Giampaolo [> >]
Henrotin, Yves mailto [Université de Liège - ULiège > Département des sciences de la motricité > Unité de recherche sur l'os et le cartillage (U.R.O.C.) - Didactique des sciences de la santé - Pathologie générale et physiopathologie >]
Dacre, Jane E [> >]
Gosset, Christiane mailto [Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique : aspects généraux >]
Jan-2001
Lancet
Lancet Publishing Group
357
251-256
Yes (verified by ORBi)
International
0140-6736
1474-547X
London
United Kingdom
[en] BACKGROUND: Treatment of osteoarthritis is usually limited to short-term symptom control. We assessed the effects of the specific drug glucosamine sulphate on the long-term progression of osteoarthritis joint structure changes and symptoms. METHODS: We did a randomised, double-blind placebo controlled trial, in which 212 patients with knee osteoarthritis were randomly assigned 1500 mg sulphate oral glucosamine or placebo once daily for 3 years. Weightbearing, anteroposterior radiographs of each knee in full extension were taken at enrolment and after 1 and 3 years. Mean joint-space width of the medial compartment of the tibiofemoral joint was assessed by digital image analysis, whereas minimum joint-space width--ie, at the narrowest point--was measured by visual inspection with a magnifying lens. Symptoms were scored by the Western Ontario and McMaster Universities (WOMAC) osteoarthritis index. FINDINGS: The 106 patients on placebo had a progressive joint-space narrowing, with a mean joint-space loss after 3 years of -0.31 mm (95% CI -0.48 to -0.13). There was no significant joint-space loss in the 106 patients on glucosamine sulphate: -0.06 mm (-0.22 to 0.09). Similar results were reported with minimum joint-space narrowing. As assessed by WOMAC scores, symptoms worsened slightly in patients on placebo compared with the improvement observed after treatment with glucosamine sulphate. There were no differences in safety or reasons for early withdrawal between the treatment and placebo groups. INTERPRETATION: The long-term combined structure-modifying and symptom-modifying effects of gluosamine sulphate suggest that it could be a disease modifying agent in osteoarthritis.
http://hdl.handle.net/2268/56763
10.1016/S0140-6736(00)03610-2

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Restricted access
Long-term effects of glucosamine sulphate on osteoarthritis progression a randomised, placebo-controlled clinical trial.pdfPublisher postprint94.25 kBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.